Prospective Study on the Prevalence of Secondary Hypertension among Hypertensive Patients Visiting a General Outpatient Clinic in Japan

Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin acti...

Full description

Saved in:
Bibliographic Details
Published inHypertension Research Vol. 27; no. 3; pp. 193 - 202
Main Authors OMURA, Masao, SAITO, Jun, YAMAGUCHI, Kunio, NISHIKAWA, Tetsuo, KAKUTA, Yukio
Format Journal Article
LanguageEnglish
Published England The Japanese Society of Hypertension 01.03.2004
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing’s syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing’s syndrome, 10 with preclinical Cushing’s syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH—a condition for which, in the present study, there were few specific signs or symptoms—while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications. (Hypertens Res 2004; 27: 193-202)
AbstractList Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing's syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing's syndrome, 10 with preclinical Cushing's syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH--a condition for which, in the present study, there were few specific signs or symptoms--while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications.
Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing’s syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing’s syndrome, 10 with preclinical Cushing’s syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH—a condition for which, in the present study, there were few specific signs or symptoms—while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications. (Hypertens Res 2004; 27: 193-202)
Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing's syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing's syndrome, 10 with preclinical Cushing's syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH--a condition for which, in the present study, there were few specific signs or symptoms--while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications.Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients. We prospectively studied 1,020 hypertensive patients. As an initial screening, we measured plasma aldosterone concentration, plasma renin activity, serum cortisol concentration and plasma catecholamine concentration and conducted abdominal ultrasonography (US). As a secondary screening, we performed furosemide plus upright test, captopril renography, dexamethasone suppression test, 24-h urine catecholamine measurement and abdominal CT. Finally, primary aldosteronism with the exception of idiopathic hyperaldosteronism, pheochromocytoma, and Cushing's syndrome were diagnosed by histopathological examination of surgical specimens. Idiopathic hyperaldosteronism was clinically diagnosed by adrenocorticotrophic hormone (ACTH)-stimulated adrenal venous sampling and renovascular hypertension by renal arteriography. There were 61 patients with primary aldosteronism, 5 with renovascular hypertension, 11 with Cushing's syndrome, 10 with preclinical Cushing's syndrome and 6 with pheochromocytoma, and the prevalence of SH was 9.1% among 1,020 hypertensive patients. In 76 (82%) of 93 patients with SH, hypertension was cured or improved after unilateral adrenalectomy, transsphenoidal pituitary adenectomy or percutaneous transluminal angioplasty. With the exception of US and CT, all initial and secondary screening tests were found to be sensitive and specific for differentiating SH from essential hypertension (EH). In conclusion, the measurement of various hormone concentrations was very sensitive for ruling out SH--a condition for which, in the present study, there were few specific signs or symptoms--while CT and US examinations were not always useful for differentiating SH from EH. The prevalence of curable SH among hypertensive subjects was higher in this study, which was conducted by our simple method of screening tests, than in previous reports. Hypertensive patients should be screened for SH and the underlying disease treated appropriately to avoid long-term use of antihypertensive drugs and risks of atherosclerotic complications.
Author YAMAGUCHI, Kunio
SAITO, Jun
NISHIKAWA, Tetsuo
OMURA, Masao
KAKUTA, Yukio
Author_xml – sequence: 1
  fullname: OMURA, Masao
  organization: Department of Medicine, Yokohama Rosai Hospital
– sequence: 1
  fullname: SAITO, Jun
  organization: Department of Medicine, Yokohama Rosai Hospital
– sequence: 1
  fullname: YAMAGUCHI, Kunio
  organization: Department of Urology, Yokohama Rosai Hospital
– sequence: 1
  fullname: NISHIKAWA, Tetsuo
  organization: Department of Medicine, Yokohama Rosai Hospital
– sequence: 1
  fullname: KAKUTA, Yukio
  organization: Department of Pathology, Yokohama Rosai Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15080378$$D View this record in MEDLINE/PubMed
BookMark eNp1kUtr3DAUhUVISSZJl90WrbrzVA-PJS3bIc2DQAbSZitk6Tqj4JFdSQ7ML-jfrorTIRS60QWd7xy495yh4zAEQOgDJUvKFP283Y8R0pKJJVX8CC0or2VVM1ofowVRtKlUw5tTdJbSMyFMrhQ9Qad0RSThQi7Qr00c0gg2-xfAD3lyezwEnLeANxFeTA_BAh46_AB2CM7EPb7ejxAzhOQLaHZDeHrzVUI2JnsIOeFHn3z2RTb4CgJE0-P7KY-zjNe9D95iH_CtGU24QO860yd4_zrP0Y9vl9_X19Xd_dXN-stdZVdC5oo51tYdU7Jlom5aBx00HCh1THWS1K3gtWlYa4QjzHEg1hlpOXOi7aRRruPn6NOcO8bh5wQp651PFvreBBimpAWVVElGCvjxFZzaHTg9Rr8r6-u_pysAnwFbLpgidNr6XJYbQo7G95oS_acgPRekmdCloOKq_nEdgv_Df53555TNExxoE7O3Pbyh-fwU00G0WxM1BP4biJ-wIA
CitedBy_id crossref_primary_10_4236_ojemd_2023_138011
crossref_primary_10_1016_j_ecl_2011_02_002
crossref_primary_10_1097_MAJ_0b013e3181e95587
crossref_primary_10_1007_s12020_022_03205_6
crossref_primary_10_1210_er_2018_00139
crossref_primary_10_14341_probl201561255_77
crossref_primary_10_1111_cen_14467
crossref_primary_10_1007_s10157_006_0420_0
crossref_primary_10_1016_j_maturitas_2013_12_009
crossref_primary_10_1213_ANE_0000000000005070
crossref_primary_10_1155_2017_8295010
crossref_primary_10_35460_2546_1621_2018_0055
crossref_primary_10_1007_s12020_020_02468_1
crossref_primary_10_1002_oby_21442
crossref_primary_10_9794_jspccs_35_46
crossref_primary_10_1053_j_jvca_2010_12_001
crossref_primary_10_1007_s11517_008_0305_3
crossref_primary_10_1016_j_carj_2014_01_001
crossref_primary_10_1016_j_currproblcancer_2014_01_001
crossref_primary_10_2217_ije_14_17
crossref_primary_10_2165_00002018_200730110_00004
crossref_primary_10_1210_clinem_dgaa982
crossref_primary_10_1161_HYPERTENSIONAHA_124_23379
crossref_primary_10_1016_j_surg_2009_11_020
crossref_primary_10_1291_hypres_29_883
crossref_primary_10_1007_s11154_010_9143_3
crossref_primary_10_1007_s00270_022_03155_6
crossref_primary_10_1038_s41440_024_01666_y
crossref_primary_10_4244_EIJV9SRA5
crossref_primary_10_1016_S0211_3449_08_73192_8
crossref_primary_10_1007_s40619_023_01394_4
crossref_primary_10_1016_j_ypmed_2016_07_007
crossref_primary_10_1136_jcp_2009_071647
crossref_primary_10_1590_S0004_27302006000100020
crossref_primary_10_1530_EJE_16_0631
crossref_primary_10_1016_j_suc_2019_04_010
crossref_primary_10_1097_HJH_0000000000001578
crossref_primary_10_1073_pnas_1121407109
crossref_primary_10_1038_hr_2014_16
crossref_primary_10_1136_bcr_2016_216209
crossref_primary_10_1007_s11102_015_0634_9
crossref_primary_10_1016_j_rce_2013_04_001
crossref_primary_10_1038_s41440_018_0128_z
crossref_primary_10_1161_01_HYP_0000258796_52134_26
crossref_primary_10_1161_HYPERTENSIONAHA_119_14601
crossref_primary_10_38109_2225_1685_2023_1_6_65
crossref_primary_10_1016_j_asjsur_2015_09_002
crossref_primary_10_1016_S1773_035X_22_00249_0
crossref_primary_10_1016_j_jash_2014_08_002
crossref_primary_10_1507_endocrj_EJ13_0060
crossref_primary_10_1161_CIRCULATIONAHA_108_189141
crossref_primary_10_3904_kjm_2017_92_4_387
crossref_primary_10_1038_hr_2010_202
crossref_primary_10_1291_hypres_30_1009
crossref_primary_10_1291_hypres_29_635
crossref_primary_10_1177_02841851211034046
crossref_primary_10_1210_js_2018_00382
crossref_primary_10_1210_js_2018_00260
crossref_primary_10_1016_j_revmed_2019_07_008
crossref_primary_10_1155_2022_9948057
crossref_primary_10_2174_1573402114666180507153549
crossref_primary_10_1007_s40618_024_02453_9
crossref_primary_10_1016_j_coemr_2019_07_001
crossref_primary_10_1507_endocrj_EJ16_0243
crossref_primary_10_1530_EJE_16_0289
crossref_primary_10_1016_j_ijcard_2007_03_002
crossref_primary_10_1210_clinem_dgac701
crossref_primary_10_1155_2016_6894381
crossref_primary_10_1371_journal_pone_0206432
crossref_primary_10_1016_S0212_8241_06_71748_0
crossref_primary_10_14341_probl201258435_41
crossref_primary_10_1016_j_kint_2022_12_021
crossref_primary_10_1111_iju_12029
crossref_primary_10_1507_endocrj_K06_180
crossref_primary_10_2174_1573402115666190416161116
crossref_primary_10_1530_EJE_15_0483
crossref_primary_10_2169_internalmedicine_50_4280
crossref_primary_10_1148_radiol_2015142159
crossref_primary_10_1291_hypres_29_9
crossref_primary_10_1016_j_crad_2012_02_005
crossref_primary_10_7326_M20_0065
crossref_primary_10_1097_HJH_0b013e3283521484
crossref_primary_10_1210_jc_2008_2766
crossref_primary_10_1177_0004563216650463
crossref_primary_10_3389_fonc_2021_724287
crossref_primary_10_1291_hypres_28_379
crossref_primary_10_1016_j_cpcardiol_2024_102791
crossref_primary_10_1291_hypres_30_1263
crossref_primary_10_1634_theoncologist_2012_0410
crossref_primary_10_1161_HYPERTENSIONAHA_119_14063
crossref_primary_10_1210_clinem_dgac379
crossref_primary_10_4158_EP15627_CR
crossref_primary_10_1016_j_mce_2019_110657
crossref_primary_10_1007_s11886_021_01609_w
crossref_primary_10_1038_jhh_2010_35
crossref_primary_10_1016_j_cqn_2013_02_001
crossref_primary_10_1038_hr_2014_129
crossref_primary_10_14442_jgfm_16_4_292
crossref_primary_10_1507_endocrj_52_435
crossref_primary_10_3390_jcm9103108
crossref_primary_10_1016_j_cpet_2013_08_008
crossref_primary_10_1053_j_jvca_2025_01_020
crossref_primary_10_1007_s40618_017_0743_6
crossref_primary_10_2176_nmc_51_72
crossref_primary_10_1038_s41440_020_0406_4
crossref_primary_10_1007_s12414_015_0035_z
crossref_primary_10_1111_iju_13060
crossref_primary_10_1093_eurheartj_eht534
crossref_primary_10_1016_j_cden_2015_08_008
crossref_primary_10_1007_s40618_025_02532_5
crossref_primary_10_1016_S0212_8241_06_71766_2
crossref_primary_10_1210_jc_2008_0125
crossref_primary_10_26442_00403660_2021_04_200678
crossref_primary_10_1016_S0716_8640_10_70569_1
crossref_primary_10_1002_ccr3_6683
crossref_primary_10_1007_s12020_012_9658_3
crossref_primary_10_11622_smedj_2018154
crossref_primary_10_5507_bp_2012_078
crossref_primary_10_1007_s40618_024_02387_2
crossref_primary_10_1016_S1885_5857_08_60143_7
crossref_primary_10_1111_cen_14375
crossref_primary_10_1007_s12020_012_9609_z
crossref_primary_10_5551_jat_4010
crossref_primary_10_1210_clinem_dgab348
crossref_primary_10_1161_HYPERTENSIONAHA_120_16429
crossref_primary_10_1016_S1889_1837_06_71631_2
crossref_primary_10_1016_j_cpet_2008_04_003
crossref_primary_10_1016_S0120_5633_11_70201_7
crossref_primary_10_1016_S0140_6736_05_67139_5
crossref_primary_10_3390_ijms23169042
crossref_primary_10_1291_hypres_29_551
crossref_primary_10_1373_clinchem_2007_087114
crossref_primary_10_1111_iju_13844
crossref_primary_10_1111_jch_14014
crossref_primary_10_1530_EJE_15_0651
crossref_primary_10_1210_clinem_dgaa606
crossref_primary_10_1097_HJH_0000000000002891
crossref_primary_10_1210_jendso_bvac049
crossref_primary_10_1159_000540205
crossref_primary_10_1007_s12020_006_0019_y
crossref_primary_10_2165_11593690_000000000_00000
crossref_primary_10_1007_s00423_011_0871_y
crossref_primary_10_1177_0267659120909770
crossref_primary_10_1210_jc_2008_0139
crossref_primary_10_2174_1874303X01306010058
crossref_primary_10_1007_s12020_024_03935_9
crossref_primary_10_1016_j_cca_2016_12_014
crossref_primary_10_1111_cen_14724
crossref_primary_10_1210_jc_2016_3206
crossref_primary_10_1253_jjcsc_13_1_109
crossref_primary_10_1007_s42000_019_00114_8
crossref_primary_10_1053_j_ackd_2015_03_001
crossref_primary_10_1111_imj_16189
crossref_primary_10_1186_s12872_023_03577_1
crossref_primary_10_38053_acmj_1455488
crossref_primary_10_1007_s00464_021_08662_0
crossref_primary_10_1507_endocrj_EJ12_0052
crossref_primary_10_31083_j_rcm_2020_04_121
crossref_primary_10_1111_hdi_12394
crossref_primary_10_1016_j_jtumed_2020_03_010
crossref_primary_10_1291_hypres_29_S1
crossref_primary_10_1507_endocrj_EJ14_0384
crossref_primary_10_1016_j_orcp_2015_07_004
crossref_primary_10_3389_fendo_2021_609263
crossref_primary_10_1157_13117734
crossref_primary_10_3389_fendo_2019_00766
crossref_primary_10_1038_ncpendmet0837
crossref_primary_10_1155_2018_4920841
crossref_primary_10_1007_s11906_006_0070_3
crossref_primary_10_1080_10641960802443282
crossref_primary_10_2169_internalmedicine_45_1855
crossref_primary_10_1016_j_pop_2012_11_008
crossref_primary_10_1016_j_euf_2015_09_011
crossref_primary_10_1210_clinem_dgae517
crossref_primary_10_1210_clinem_dgaa954
crossref_primary_10_1016_j_jacc_2020_02_052
crossref_primary_10_1097_CCM_0000000000002333
crossref_primary_10_23736_S0391_1977_18_02884_5
crossref_primary_10_1507_endocrj_KR_105
crossref_primary_10_1210_jendso_bvab085
crossref_primary_10_1016_j_nucmedbio_2008_05_005
crossref_primary_10_1007_s40618_020_01197_6
crossref_primary_10_1186_s12301_021_00265_4
crossref_primary_10_1530_EJE_17_0077
crossref_primary_10_1007_s11154_007_9055_z
crossref_primary_10_1111_jch_12713
crossref_primary_10_1007_s40292_016_0153_4
crossref_primary_10_3109_08037051_2013_867655
crossref_primary_10_1016_j_jemermed_2017_05_032
crossref_primary_10_4061_2011_598694
crossref_primary_10_4082_kjfm_2010_31_6_420
crossref_primary_10_1016_j_jacc_2022_08_714
crossref_primary_10_1016_j_surg_2006_07_026
crossref_primary_10_1161_CIRCULATIONAHA_114_008544
crossref_primary_10_1161_CIRCRESAHA_116_303647
crossref_primary_10_1210_clinem_dgz293
crossref_primary_10_1161_HYPERTENSIONAHA_114_04619
crossref_primary_10_1016_j_surg_2023_04_010
crossref_primary_10_1373_clinchem_2014_233551
crossref_primary_10_1161_HYPERTENSIONAHA_121_18118
crossref_primary_10_1507_endocrj_EJ19_0498
crossref_primary_10_1159_000515652
crossref_primary_10_1155_2014_794187
crossref_primary_10_1291_hypres_30_1083
crossref_primary_10_1080_10253890701395896
crossref_primary_10_4103_cdrp_cdrp_3_24
crossref_primary_10_2169_internalmedicine_1218_18
crossref_primary_10_1586_eem_12_65
crossref_primary_10_4103_jdap_jdap_43_24
crossref_primary_10_1016_j_steroids_2013_02_005
crossref_primary_10_1093_ajh_hpad022
crossref_primary_10_1097_MD_0000000000000708
crossref_primary_10_1155_2013_321063
crossref_primary_10_1161_HYPERTENSIONAHA_108_189141
crossref_primary_10_1016_j_cca_2010_01_012
crossref_primary_10_1016_j_jccase_2021_08_001
crossref_primary_10_1038_hr_2010_166
crossref_primary_10_1111_jch_14339
crossref_primary_10_2169_internalmedicine_50_4351
crossref_primary_10_4065_84_2_180
crossref_primary_10_1093_ejendo_lvad140
crossref_primary_10_2169_internalmedicine_55_5196
crossref_primary_10_1507_endocrj_EJ19_0262
crossref_primary_10_1097_MED_0b013e32835ef2fd
crossref_primary_10_1186_s43044_024_00556_5
crossref_primary_10_1038_s41440_023_01461_1
crossref_primary_10_1007_s00268_014_2461_y
crossref_primary_10_1157_13119966
crossref_primary_10_1038_s41371_019_0272_1
crossref_primary_10_1177_145749690409300409
crossref_primary_10_1016_j_nucmedbio_2018_11_002
crossref_primary_10_1097_HJH_0b013e328360ddf6
crossref_primary_10_7314_APJCP_2015_16_12_5031
crossref_primary_10_1080_10641963_2017_1339072
crossref_primary_10_1097_HJH_0000000000001885
crossref_primary_10_1007_s40618_024_02450_y
crossref_primary_10_5005_jp_journals_10002_1314
crossref_primary_10_1210_jc_2018_00059
crossref_primary_10_1210_endrev_bnad011
crossref_primary_10_3399_bjgp18X694589
crossref_primary_10_1177_1066896911427036
crossref_primary_10_3389_fendo_2021_605797
crossref_primary_10_3390_cancers14163845
crossref_primary_10_1258_om_2010_090063
crossref_primary_10_2169_naika_96_2539
crossref_primary_10_3390_cancers11030318
crossref_primary_10_1111_j_1365_2753_2012_01873_x
crossref_primary_10_1161_CIRCEP_121_007960
crossref_primary_10_1097_MD_0000000000031313
crossref_primary_10_1186_1758_5996_2_71
crossref_primary_10_3390_jcm12030874
crossref_primary_10_1097_HJH_0000000000003252
crossref_primary_10_1097_HJH_0000000000002047
crossref_primary_10_36290_kar_2019_036
crossref_primary_10_1507_endocrj_EJ12_0270
crossref_primary_10_1507_endocrj_EJ13_0353
crossref_primary_10_1038_s41598_023_47967_z
crossref_primary_10_17925_EE_2023_19_2_11
crossref_primary_10_38109_2075_082X_2024_4_5_109
crossref_primary_10_1002_ccr3_6932
crossref_primary_10_1038_s41440_021_00663_9
crossref_primary_10_2478_enr_2022_0028
crossref_primary_10_15829_1728_8800_2019_2_84_93
crossref_primary_10_1161_HYPERTENSIONAHA_119_14341
crossref_primary_10_1136_bcr_2020_238380
crossref_primary_10_1111_jch_14558
crossref_primary_10_1186_s12902_020_0490_0
crossref_primary_10_17650_1818_8338_2018_12_1_43_50
crossref_primary_10_1038_hr_2006_143
crossref_primary_10_1097_MED_0b013e3283390f8d
crossref_primary_10_1007_s11695_011_0545_4
crossref_primary_10_1007_s13730_017_0299_5
crossref_primary_10_1158_1078_0432_CCR_16_0384
crossref_primary_10_1089_end_2007_9884
crossref_primary_10_1111_jch_12916
crossref_primary_10_4236_ojneph_2016_63012
crossref_primary_10_1007_s11886_014_0528_x
crossref_primary_10_1016_j_aan_2016_08_001
crossref_primary_10_1161_HYPERTENSIONAHA_116_08519
crossref_primary_10_4158_EP09023OR
crossref_primary_10_2169_internalmedicine_47_0333
crossref_primary_10_1111_jch_12920
crossref_primary_10_1136_bcr_2013_009491
crossref_primary_10_1136_pgmj_2011_118661
crossref_primary_10_1016_j_revmed_2009_08_015
crossref_primary_10_2169_naika_97_2155
crossref_primary_10_2214_AJR_12_9126
crossref_primary_10_3389_fendo_2024_1372683
crossref_primary_10_3904_kjim_2018_231
crossref_primary_10_1097_MED_0000000000000729
crossref_primary_10_1007_s11886_019_1185_x
crossref_primary_10_1093_ejendo_lvac016
crossref_primary_10_1016_j_ecl_2019_08_006
crossref_primary_10_1111_j_1442_2042_2012_03014_x
crossref_primary_10_1016_j_ecl_2019_08_002
crossref_primary_10_3803_EnM_2020_35_1_157
crossref_primary_10_1038_hr_2013_107
crossref_primary_10_1016_j_beem_2019_101346
crossref_primary_10_1177_0004563217739931
crossref_primary_10_2169_naika_95_482
crossref_primary_10_1016_j_asjsur_2014_01_011
crossref_primary_10_1016_j_steroids_2019_108470
crossref_primary_10_1053_j_jvca_2021_03_034
crossref_primary_10_3389_fendo_2022_861581
crossref_primary_10_1507_endocrj_K07E_164
crossref_primary_10_1016_j_surg_2018_05_085
crossref_primary_10_1007_s00423_021_02245_2
crossref_primary_10_1016_S1889_1837_06_71658_0
crossref_primary_10_1016_S1479_666X_07_80026_6
crossref_primary_10_1186_1532_429X_14_28
crossref_primary_10_1016_j_plabm_2016_05_001
crossref_primary_10_1507_endocrj_EJ12_0247
crossref_primary_10_1016_j_jvir_2013_01_007
crossref_primary_10_1016_j_beem_2006_07_011
crossref_primary_10_1007_s11906_012_0246_y
crossref_primary_10_1007_s40618_020_01484_2
crossref_primary_10_1177_2054270417698632
crossref_primary_10_1507_endocrj_EJ11_0133
crossref_primary_10_11622_smedj_2021135
crossref_primary_10_23736_S2724_5276_18_05319_7
crossref_primary_10_1245_s10434_012_2670_2
crossref_primary_10_1080_10408360600931831
crossref_primary_10_2169_naika_101_605
crossref_primary_10_1016_j_beem_2019_101365
crossref_primary_10_1177_2048004021992191
crossref_primary_10_1210_jc_2016_1673
crossref_primary_10_1507_endocrj_K10E_402
crossref_primary_10_1507_endocrj_EJ22_0585
crossref_primary_10_1007_s12349_009_0053_4
crossref_primary_10_1016_j_eprac_2020_10_016
crossref_primary_10_1097_HJH_0b013e328362152e
crossref_primary_10_1111_1556_4029_12107
crossref_primary_10_3389_fonc_2022_979994
crossref_primary_10_1016_j_med_2020_10_013
crossref_primary_10_4236_ojrad_2017_74024
crossref_primary_10_1186_s40981_018_0212_z
crossref_primary_10_1210_js_2019_00226
crossref_primary_10_1038_s41440_021_00710_5
crossref_primary_10_1038_nrendo_2011_51
crossref_primary_10_1007_s40292_018_0288_6
crossref_primary_10_4137_JCM_S6316
crossref_primary_10_1016_j_cca_2017_12_026
crossref_primary_10_1053_j_ackd_2019_03_002
crossref_primary_10_1291_hypres_30_103
crossref_primary_10_1111_j_1742_7843_2011_00758_x
crossref_primary_10_1007_s12020_011_9588_5
crossref_primary_10_1186_1471_2261_12_38
crossref_primary_10_1631_jzus_B1600411
crossref_primary_10_1507_endocrj_K09E_014
crossref_primary_10_2169_internalmedicine_0891_18
crossref_primary_10_1186_s12957_019_1649_x
crossref_primary_10_1210_jc_2019_00996
crossref_primary_10_1016_j_cvsm_2009_10_005
crossref_primary_10_1016_j_ando_2022_02_001
crossref_primary_10_1291_hypres_30_111
crossref_primary_10_1007_s12020_017_1300_y
crossref_primary_10_1007_s00268_005_0594_8
crossref_primary_10_1210_jc_2014_1498
Cites_doi 10.1053/meta.2002.30498
10.1016/0002-9343(65)90122-1
10.1016/S0025-6196(11)62105-8
10.1097/00004872-199715010-00006
10.1536/ihj.26.549
10.1097/00004872-200306000-00001
10.1291/hypres.24.613
10.1016/S0140-6736(00)04223-9
10.1291/hypres.25.553
10.3109/10641968109037426
10.1001/archinte.147.7.1289
10.1148/radiology.212.2.r99au20378
10.1111/j.0954-6820.1981.tb11628.x
10.1210/jc.86.8.4003
10.1016/S0753-3322(00)80019-0
10.1046/j.1365-2265.2002.01613.x
10.1093/qjmed/90.1.51
10.1001/archinte.141.12.1589
10.1097/00004872-199405000-00015
10.1097/00004872-199816100-00018
10.1016/S0140-6736(00)04172-6
10.1210/jc.85.5.1863
10.1001/archinte.1965.03870020012006
10.1001/jama.289.18.2363
10.1016/S0895-7061(02)02969-2
10.1002/ccd.10387
10.1016/S0889-8529(02)00013-0
10.1093/ndt/gfg121
10.1210/jc.86.9.4292
10.1111/j.1440-1681.1994.tb02519.x
10.1161/01.HYP.0000038478.59760.41
10.1210/jc.85.8.2854
ContentType Journal Article
Copyright 2004 by the Japanese Society of Hypertension
Copyright_xml – notice: 2004 by the Japanese Society of Hypertension
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1291/hypres.27.193
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1348-4214
EndPage 202
ExternalDocumentID 15080378
10_1291_hypres_27_193
article_hypres_27_3_27_3_193_article_char_en
Genre Journal Article
GroupedDBID ---
-Q-
.55
0R~
29I
2WC
39C
4.4
406
53G
5GY
70F
7X7
88E
8FI
8FJ
AACDK
AANZL
AASML
AATNV
ABAKF
ABAWZ
ABBRH
ABDBE
ABFSG
ABJNI
ABLJU
ABRTQ
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACMJI
ACRQY
ACSTC
ACZOJ
ADBBV
AEFQL
AEJRE
AEMSY
AENEX
AESKC
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFHIU
AFKRA
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AHWEU
AIGIU
AILAN
AIXLP
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ATHPR
AXYYD
AYFIA
BAWUL
BENPR
BKKNO
BPHCQ
BVXVI
CCPQU
CS3
DIK
DNIVK
DPUIP
DU5
E3Z
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMOBN
F5P
FDQFY
FERAY
FIGPU
FIZPM
FSGXE
FYUFA
GX1
HMCUK
HZ~
IWAJR
JSF
JSH
JSO
JZLTJ
KQ8
LGEZI
LOTEE
M1P
NADUK
NQJWS
NXXTH
O9-
OK1
P2P
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RJT
RNT
RNTTT
ROL
RZJ
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TKC
TR2
TSG
UKHRP
W2D
X7M
XSB
AAYXX
ACMFV
ALIPV
CITATION
3V.
AAZLF
ADHDB
CGR
CUY
CVF
ECM
EIF
NAO
NPM
7X8
ID FETCH-LOGICAL-c578t-2d2b4f298b2746bdefe63e11d29f804b734a62ba7d02d3e0cda8c32d7bf8a9df3
ISSN 0916-9636
IngestDate Fri Jul 11 01:23:26 EDT 2025
Wed Feb 19 01:37:53 EST 2025
Tue Jul 01 01:54:25 EDT 2025
Thu Apr 24 23:08:42 EDT 2025
Wed Sep 03 06:30:03 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c578t-2d2b4f298b2746bdefe63e11d29f804b734a62ba7d02d3e0cda8c32d7bf8a9df3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/hypres/27/3/27_3_193/_article/-char/en
PMID 15080378
PQID 71819820
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_71819820
pubmed_primary_15080378
crossref_citationtrail_10_1291_hypres_27_193
crossref_primary_10_1291_hypres_27_193
jstage_primary_article_hypres_27_3_27_3_193_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2004-03-01
PublicationDateYYYYMMDD 2004-03-01
PublicationDate_xml – month: 03
  year: 2004
  text: 2004-03-01
  day: 01
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Hypertension Research
PublicationTitleAlternate Hypertension Research
PublicationYear 2004
Publisher The Japanese Society of Hypertension
Publisher_xml – name: The Japanese Society of Hypertension
References 36. Morganti A: Angioplasty of the renal artery: antihypertensive and renal effects. J Nephrol 2000; 13 (Suppl): S28-S33.
18. Ross EJ: Conn’s syndrome due to adrenal hyperplasia with hypertrophy of zona glomerulosa, relieved by unilateral adrenalectomy. Am J Med 1965; 39: 994-1001.
6. Gordon RD, Stowasser M, Tunny TJ, et al: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318.
15. Nugent CA, Nicholis T, Tyler FH: Diagnosis of Cushing’s syndrome: single dose dexamethasone suppression test. Arch Intern Med 1965; 116: 172-176.
22. Boscaro M, Barzon L, Fallo F, et al: Cushing’s syndrome. Lancet 2001; 357: 783-791.
2. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
13. Mikami K, Nishikawa T, Tamura Y, et al: Inter-relationship of sympathetic nervous system and renin-angiotensin-aldosterone system in three renin subgroups of borderline and persistent essential hypertension. Clin Exp Hypertens 1981; 3: 1091-1107.
27. Fardella CE, Mosso L, Gómez-Sánchez C, et al: Primary aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.
32. Yamashita T, Ito F, Iwakiri N, et al: Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. Hypertens Res 2002; 25: 553-557.
35. Xue F, Bettmann MA, Langdon DR, et al: Outcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting. Radiology 1999; 212: 378-384.
19. Guideline Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
16. Naomi S, Iwaoka T, Umeda T, et al: Clinical evaluation of captopril screening test for primary aldosteronism. Jpn Heart J 1985; 26: 549-556.
4. Danielson M, Dammström B: The prevalence of secondary and curable hypertension. Acta Med Scand 1981; 209: 451-455.
12. Anderson GH Jr, Blakeman N, Streeten DHP: The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994; 12: 609-615.
25. Montori VM, Schwartz GL, Chapman AB, et al: Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001: 76: 877-882.
10. Rossi E, Regolisti G, Negro A, et al: High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.
28. Hirohara D, Nomura K, Okamoto T, et al: Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 2001; 86: 4292-4298.
17. Omura M, Sasano H, Fujiwara T, et al: Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selected adrenal venous sampling. Metabolism 2002; 51: 350-355.
29. Montori VM, Young WF Jr: Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31: 619-632.
7. Komiya I, Yamada T, Takasu N, et al: An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system. J Hypertens 1997; 15: 65-72.
3. Rudnick KV, Sackett DL, Hirst S, et al: Hypertension in a family practice. Can Med Assoc J 1977; 117: 492-497.
1. Wolf-Maier K, Cooper RS, Banegas JR, et al: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.
5. Sinclair AM, Isles CG, Brown I, et al: Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289-1293.
26. Hiramatsu K, Yamada T, Yukimura Y, et al: A screening test to identify aldosterone-producing adenoma by measurement plasma renin activity. Arch Intern Med 1981; 141: 1589-1593.
14. Helin KH, Tikkanen I, von Knorring JE, et al: Screening for renovascular hypertension in a population with relatively low prevalence. J Hypertens 1998; 16: 1523-1529.
31. Van Ampting JM, Penne EL, Beek FJ, et al: Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003; 18: 1147-1151.
24. Seifarth C, Trenkel S, Schobel H, et al: Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57: 457-465.
8. Lim PO, Rodgers P, Cardale K, et al: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353: 40.
11. Nishikawa T, Omura M: Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54 (Suppl 1): 83s-85s.
21. Loh KC, Shlossberg AH, Abbott EC, et al: Phaeochromocytoma: a ten-year survey. QJM 1997; 90: 51-60.
23. Mulatero P, Rabbia F, Milan A, et al: Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902.
33. Khosla S, Kunjummen B, Manda R, et al: Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography. Cathet Cardiovasc Intervent 2003; 58: 400-403.
20. Fardella CE, Mosso L: Author’s response; prevalence of primary aldosteronism in unselected hypertensive populations: screening and definitive diagnosis. J Clin Endocrinol Metab 2001; 86: 4003-4004.
30. Kaplan NM: Caution over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953-954.
9. Loh K, Koay E, Khaw M, et al: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859.
34. Martinez-Amenos A, Rama H, Sarrias X, et al: Percutaneous transluminal angioplasty in the treatment of renovascular hypertension. J Hum Hypertens 1991; 5: 97-100.
22
23
24
Montori VM, Schwartz GL, Chapman AB (25) 2001; 76
26
(6) 1994; 21
27
Lim PO, Rodgers P, Cardale K, et al (8) 1999; 353
28
Rudnick KV, Sackett DL, Hirst S, et (3) 1977; 117
Montori VM, Young WF Jr (29) 2002; 31
Xue F, Bettmann MA, Langdon DR, et (35) 1999; 212
Mikami K, Nishikawa T, Tamura Y, et (13) 1981; 3
Loh KC, Shlossberg AH, Abbott EC, e (21) 1997; 90
Nugent CA, Nicholis T, Tyler FH (15) 1965; 116
Anderson GH Jr, Blakeman N, Streete (12) 1994; 12
NAOMI S (16) 1985; 26
30
10
32
14
17
18
19
Nishikawa T, Omura M (11) 2000; 54 (Suppl 1)
Khosla S, Kunjummen B, Manda R, et (33) 2003; 58
1
Danielson M, Dammström B (4) 1981; 209
Martinez-Amenos A, Rama H, Sarrias (34) 1991; 5
5
7
Morganti A (36) 2000; 13(Suppl)
Van Ampting JM, Penne EL, Beek FJ (31) 2003; 18
9
Japanese Society of Hypertension Gu (2) 2001; 24
20
References_xml – reference: 1. Wolf-Maier K, Cooper RS, Banegas JR, et al: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.
– reference: 22. Boscaro M, Barzon L, Fallo F, et al: Cushing’s syndrome. Lancet 2001; 357: 783-791.
– reference: 10. Rossi E, Regolisti G, Negro A, et al: High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.
– reference: 3. Rudnick KV, Sackett DL, Hirst S, et al: Hypertension in a family practice. Can Med Assoc J 1977; 117: 492-497.
– reference: 13. Mikami K, Nishikawa T, Tamura Y, et al: Inter-relationship of sympathetic nervous system and renin-angiotensin-aldosterone system in three renin subgroups of borderline and persistent essential hypertension. Clin Exp Hypertens 1981; 3: 1091-1107.
– reference: 29. Montori VM, Young WF Jr: Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31: 619-632.
– reference: 24. Seifarth C, Trenkel S, Schobel H, et al: Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57: 457-465.
– reference: 8. Lim PO, Rodgers P, Cardale K, et al: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353: 40.
– reference: 4. Danielson M, Dammström B: The prevalence of secondary and curable hypertension. Acta Med Scand 1981; 209: 451-455.
– reference: 20. Fardella CE, Mosso L: Author’s response; prevalence of primary aldosteronism in unselected hypertensive populations: screening and definitive diagnosis. J Clin Endocrinol Metab 2001; 86: 4003-4004.
– reference: 17. Omura M, Sasano H, Fujiwara T, et al: Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selected adrenal venous sampling. Metabolism 2002; 51: 350-355.
– reference: 27. Fardella CE, Mosso L, Gómez-Sánchez C, et al: Primary aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.
– reference: 2. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
– reference: 14. Helin KH, Tikkanen I, von Knorring JE, et al: Screening for renovascular hypertension in a population with relatively low prevalence. J Hypertens 1998; 16: 1523-1529.
– reference: 30. Kaplan NM: Caution over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953-954.
– reference: 9. Loh K, Koay E, Khaw M, et al: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859.
– reference: 35. Xue F, Bettmann MA, Langdon DR, et al: Outcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting. Radiology 1999; 212: 378-384.
– reference: 28. Hirohara D, Nomura K, Okamoto T, et al: Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 2001; 86: 4292-4298.
– reference: 26. Hiramatsu K, Yamada T, Yukimura Y, et al: A screening test to identify aldosterone-producing adenoma by measurement plasma renin activity. Arch Intern Med 1981; 141: 1589-1593.
– reference: 33. Khosla S, Kunjummen B, Manda R, et al: Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography. Cathet Cardiovasc Intervent 2003; 58: 400-403.
– reference: 7. Komiya I, Yamada T, Takasu N, et al: An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system. J Hypertens 1997; 15: 65-72.
– reference: 11. Nishikawa T, Omura M: Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54 (Suppl 1): 83s-85s.
– reference: 31. Van Ampting JM, Penne EL, Beek FJ, et al: Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003; 18: 1147-1151.
– reference: 23. Mulatero P, Rabbia F, Milan A, et al: Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902.
– reference: 34. Martinez-Amenos A, Rama H, Sarrias X, et al: Percutaneous transluminal angioplasty in the treatment of renovascular hypertension. J Hum Hypertens 1991; 5: 97-100.
– reference: 16. Naomi S, Iwaoka T, Umeda T, et al: Clinical evaluation of captopril screening test for primary aldosteronism. Jpn Heart J 1985; 26: 549-556.
– reference: 21. Loh KC, Shlossberg AH, Abbott EC, et al: Phaeochromocytoma: a ten-year survey. QJM 1997; 90: 51-60.
– reference: 32. Yamashita T, Ito F, Iwakiri N, et al: Prevalence and predictors of renal artery stenosis in patients undergoing cardiac catheterization. Hypertens Res 2002; 25: 553-557.
– reference: 25. Montori VM, Schwartz GL, Chapman AB, et al: Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001: 76: 877-882.
– reference: 6. Gordon RD, Stowasser M, Tunny TJ, et al: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318.
– reference: 12. Anderson GH Jr, Blakeman N, Streeten DHP: The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994; 12: 609-615.
– reference: 36. Morganti A: Angioplasty of the renal artery: antihypertensive and renal effects. J Nephrol 2000; 13 (Suppl): S28-S33.
– reference: 18. Ross EJ: Conn’s syndrome due to adrenal hyperplasia with hypertrophy of zona glomerulosa, relieved by unilateral adrenalectomy. Am J Med 1965; 39: 994-1001.
– reference: 15. Nugent CA, Nicholis T, Tyler FH: Diagnosis of Cushing’s syndrome: single dose dexamethasone suppression test. Arch Intern Med 1965; 116: 172-176.
– reference: 5. Sinclair AM, Isles CG, Brown I, et al: Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289-1293.
– reference: 19. Guideline Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
– ident: 17
  doi: 10.1053/meta.2002.30498
– ident: 18
  doi: 10.1016/0002-9343(65)90122-1
– volume: 76
  start-page: 877
  issn: 0025-6196
  year: 2001
  ident: 25
  publication-title: Mayo Clin Proc
  doi: 10.1016/S0025-6196(11)62105-8
– ident: 7
  doi: 10.1097/00004872-199715010-00006
– volume: 26
  start-page: 549
  issn: 0021-4868
  issue: 4
  year: 1985
  ident: 16
  publication-title: Jpn Heart J
  doi: 10.1536/ihj.26.549
– ident: 19
  doi: 10.1097/00004872-200306000-00001
– volume: 5
  start-page: 97
  issn: 0950-9240
  year: 1991
  ident: 34
  publication-title: J Hum Hypertens
– volume: 24
  start-page: 613
  issn: 0916-9636
  year: 2001
  ident: 2
  publication-title: Hypertens Res
  doi: 10.1291/hypres.24.613
– ident: 30
  doi: 10.1016/S0140-6736(00)04223-9
– ident: 32
  doi: 10.1291/hypres.25.553
– volume: 3
  start-page: 1091
  issn: 0730-0077
  year: 1981
  ident: 13
  publication-title: Clin Exp Hypertens
  doi: 10.3109/10641968109037426
– ident: 5
  doi: 10.1001/archinte.147.7.1289
– volume: 212
  start-page: 378
  issn: 0033-8419
  year: 1999
  ident: 35
  publication-title: Radiology
  doi: 10.1148/radiology.212.2.r99au20378
– volume: 209
  start-page: 451
  issn: 0001-6101
  year: 1981
  ident: 4
  publication-title: Acta Med Scand
  doi: 10.1111/j.0954-6820.1981.tb11628.x
– ident: 20
  doi: 10.1210/jc.86.8.4003
– volume: 54 (Suppl 1)
  start-page: 83s
  issn: 0753-3322
  year: 2000
  ident: 11
  publication-title: Biomed Pharmacother
  doi: 10.1016/S0753-3322(00)80019-0
– ident: 24
  doi: 10.1046/j.1365-2265.2002.01613.x
– volume: 90
  start-page: 51
  issn: 1460-2725
  year: 1997
  ident: 21
  publication-title: QJM
  doi: 10.1093/qjmed/90.1.51
– ident: 26
  doi: 10.1001/archinte.141.12.1589
– volume: 12
  start-page: 609
  issn: 0263-6352
  year: 1994
  ident: 12
  publication-title: J Hypertens
  doi: 10.1097/00004872-199405000-00015
– volume: 117
  start-page: 492
  issn: 0820-3946
  year: 1977
  ident: 3
  publication-title: Can Med Assoc J
– ident: 14
  doi: 10.1097/00004872-199816100-00018
– ident: 22
  doi: 10.1016/S0140-6736(00)04172-6
– ident: 27
  doi: 10.1210/jc.85.5.1863
– volume: 116
  start-page: 172
  issn: 0003-9926
  year: 1965
  ident: 15
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.1965.03870020012006
– ident: 1
  doi: 10.1001/jama.289.18.2363
– ident: 10
  doi: 10.1016/S0895-7061(02)02969-2
– volume: 58
  start-page: 400
  year: 2003
  ident: 33
  publication-title: Cathet Cardiovasc Intervent
  doi: 10.1002/ccd.10387
– volume: 31
  start-page: 619
  issn: 0889-8529
  year: 2002
  ident: 29
  publication-title: Endocrinol Metab Clin North Am
  doi: 10.1016/S0889-8529(02)00013-0
– volume: 18
  start-page: 1147
  issn: 0931-0509
  year: 2003
  ident: 31
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfg121
– ident: 28
  doi: 10.1210/jc.86.9.4292
– volume: 21
  start-page: 315
  issn: 0305-1870
  issue: 4
  year: 1994
  ident: 6
  publication-title: Clin Exp Pharmacol Physiol
  doi: 10.1111/j.1440-1681.1994.tb02519.x
– ident: 23
  doi: 10.1161/01.HYP.0000038478.59760.41
– volume: 353
  start-page: 40
  issn: 0140-6736
  year: 1999
  ident: 8
  publication-title: Lancet
– ident: 9
  doi: 10.1210/jc.85.8.2854
– volume: 13(Suppl)
  start-page: S28
  issn: 1120-3625
  year: 2000
  ident: 36
  publication-title: J Nephrol
SSID ssj0028591
Score 2.2725716
Snippet Secondary hypertension (SH) including endocrine hypertension has been reported to be uncommon. We estimated the prevalence of SH among hypertensive patients....
SourceID proquest
pubmed
crossref
jstage
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 193
SubjectTerms Adrenal Gland Diseases - diagnosis
Adrenal Gland Diseases - surgery
Adrenal Gland Neoplasms - complications
Adrenal Gland Neoplasms - diagnosis
Adrenal Gland Neoplasms - surgery
Adrenalectomy
Ambulatory Care Facilities - statistics & numerical data
Angioplasty, Balloon
Cushing Syndrome - complications
Cushing Syndrome - diagnosis
Cushing Syndrome - surgery
Cushing’s syndrome
Humans
Hyperaldosteronism - complications
Hyperaldosteronism - diagnosis
Hyperaldosteronism - surgery
Hypertension - epidemiology
Hypertension - etiology
Hypertension, Renovascular - diagnosis
Hypertension, Renovascular - therapy
Mass Screening
pheochromocytoma
Pheochromocytoma - complications
Pheochromocytoma - diagnosis
Pheochromocytoma - surgery
Pituitary Gland - surgery
Prevalence
primary aldosteronism
Prospective Studies
renovascular hypertension
secondary hypertension
Sensitivity and Specificity
Treatment Outcome
Title Prospective Study on the Prevalence of Secondary Hypertension among Hypertensive Patients Visiting a General Outpatient Clinic in Japan
URI https://www.jstage.jst.go.jp/article/hypres/27/3/27_3_193/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/15080378
https://www.proquest.com/docview/71819820
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Hypertension Research, 2004, Vol.27(3), pp.193-202
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgQYgL4k15-oC4lCyJ48aJOCHYVdnd7nJope4psmNnKcsmqE0u_AH-NuNHnFSw4nGJKmfqpPk-T2cmnhmEXgolMhoWRcDlhAcUHADQg4IGE8Z0wTldgE8H9GfHyXRBD5aTZR_KNtkljdgtvv82r-R_UIUxwFVnyf4Dsn5SGIDPgC8cAWE4_hXGn9Z1lylp68S60L_O_IfrmEULxuBGO71Sb4_7DF7n2uxZ15uQTZ-hfggmcVVWN2Odcm42RHPdY1nHrcZ127jTLp1Sh0oO4L-2Ghq40-EVXCUhH3E-uWhNW6PxjG947YM7fNXY9z-tZ-opv-Bnuk-LUURttfLSh_y8tRbvaXvuhruoBe23bXXhxygJYPEnQ01sqwQ4xsUDtRrZLoq_qHuSaXUPDwp-zy5hu05uu6z28Um-vzg6yud7y_lVdI2AP6FbXXz4eOg9c13EzxRldDflirHC9G-2Jt8yXq5_Afv9TF3umhgTZX4b3XK-BX5niXIHXVHVXXRj5nZP3EM_BnzBhi-4rjDwBfd8wXWJPV_wkC_Y8AUP-YI7vuCOL5hjxxfc8wVbvuBVhQ1f7qPF_t78_TRwjTiCAhR6ExBJBC1JlgrCaCKkKlUSqyiSJCvTkAoWU54QwZkMiYxVWEieFjGRTJQpz2QZP0A7VV2pRwjLiIiERykFFUHTpBBcMRWnKiqzMGVZMUKvuyecF65KvW6W8jXX3ioAkltAcsJyAGSEXnnxb7Y8y2WCby1cXsyt2oFYbA8g7U_q1EfQNCP0osM4B_Wr36nxStXtJgfTLsrAih6hhxb6_jbA9Qljlj7-43efoJv9EnmKdpp1q56BqduI54amPwGHz7jj
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prospective+study+on+the+prevalence+of+secondary+hypertension+among+hypertensive+patients+visiting+a+general+outpatient+clinic+in+Japan&rft.jtitle=Hypertension+research&rft.au=Omura%2C+Masao&rft.au=Saito%2C+Jun&rft.au=Yamaguchi%2C+Kunio&rft.au=Kakuta%2C+Yukio&rft.date=2004-03-01&rft.issn=0916-9636&rft.volume=27&rft.issue=3&rft.spage=193&rft_id=info:doi/10.1291%2Fhypres.27.193&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0916-9636&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0916-9636&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0916-9636&client=summon